The origin of cancers is associated with etiology as well as therapeutics. Several studies reveal that malignancies in children can originate in utero. However, a diagnostic approach to distinguish between cancers initiated pre-or postnatally is absent. Here we identified a transcriptional factor FEV (fifth Ewing variant) that was expressed in fetal hematopoietic cells and became silent after birth. We characterized that FEV was essential for the self-renewal of hematopoietic stem cells (HSCs). We next found that FEV was expressed in most infant leukemia samples, but seldom in adult samples, in accord with the known prenatal origins of the former. We further determined the majority of pediatric acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML) were FEV positive. Moreover, FEV knockdown markedly impaired the leukemia-propagating ability of leukemic stem cells. We therefore identified FEV is unique to fetal HSCs and stably expressed in leukemic cells of prenatal origin. It may also provide a tractable therapeutic target.
INTRODUCTION
Recognition of embryonal features in cancer cells presumes the possibility of a prenatal origin for cancer. [1] [2] [3] Since the first demonstrations that leukemogenic chromosome translocations can occur prenatally, 4 increasing evidence supports that a substantial number of malignancies in children and adolescent can originate prenatally. [5] [6] [7] [8] [9] [10] [11] [12] [13] However, there is currently no diagnostic test or biomarker that distinguishes cancers that are pre-versus post-natal in origin. FEV (fifth Ewing variant) expression may provide such a test. FEV (also known as PET1 in mammals) is an ETS (E26 transformation-specific) transcription factor.
14, 15 We previously reported that this transcription factor is essential for embryonic development of hemogenic endothelium-based hematopoietic stem cells (HSCs) and for its functional maintenance in fetal hematopoiesis. 16 Yet, it remains to be confirmed whether FEV regulates the selfrenewal in HSCs or plays other roles. In the current study, we systemically analyzed the developmental profile of FEV expression and characterized its functional roles in HSCs. Furthermore, we investigated FEV expression in leukemic cells in terms of its correlation with origins of the disease and its effect on leukemia propagation of leukemic stem cells (LSCs). We demonstrated that FEV is a specific regulator of self-renewal in fetal HSCs. FEV expression is essential for leukemia propagation of LSCs and is reflective of the common prenatal initiation of the disease.
MATERIALS AND METHODS

Human samples
Umbilical vein cord blood (CB) from anonymized healthy donors was purchased from Shanghai Cord Blood Bank (Shanghai, China) in accordance with local ethics procedures. Clinical Samples of fetal liver and bone marrow (BM) from healthy donors and leukemia patients were obtained from Shanghai Jiaotong University and Fudan University (Shanghai, China)-affiliated hospitals and the studies were approved by their medical ethical committees and all human participants gave written informed consent. Detailed information of the clinical samples is described in Supplementary Tables  S1-S3. Reverse-transcriptase quantitative PCR (RT-qPCR) detection of FEV expression and the positivity definition Total RNA was extracted by Trizol reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA) and reversely transcribed. RT-qPCR was performed using SYBR Green PCR master mix (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. All experiments were performed in triplicate with Applied Biosystems 7900HT. Differences in complementary DNA input were normalized by glucuronidase beta (GUS) expression levels. 17, 18 Samples with GUS cycle threshold values of ⩾ 30 were excluded from the analysis. The positivity for FEV expression is defined according to amplification in at least two of three replicates with FEV cycle threshold values of ⩽ 40 (using a threshold setting of 0.1) and a single melt peak (FEV at 92°C; GUS at 89.5°C). 17 The detail is described in Supplementary Methods. Preparation of lentivirus and transduction FEV interference oligonucleotides (cat. no. RHS4533) were purchased from Open Biosystems (Huntsville, CO, USA). Lentiviruses were packaged as previously described. 19 Lin − CD34 + CD38 − cells or acute myeloid leukemia (AML) LSCs or acute lymphoid leukemia (ALL) cells were infected with lentivirus at a multiplicity of infection of 100 for 18 h. Transduced cells were either transplanted into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice or used for in vitro assays.
Colony-forming cell (CFC) assay
Assays were performed in a semisolid methylcellulose medium as previously described. 20 Cells were plated in 35 mm dishes containing methylcellulose. The colonies were scored under a microscope 13-14 days post plating. Replating was carried out by pooling total cells from primary cultures and inoculating 10 5 into fresh methylcellulose medium.
Long-term culture-initiating cell (LTC-IC) assay
Limiting dilution LTC-IC assay was performed in 96-well format in myelocult H5100 medium (Stem Cell Technologies, Vancouver, BC, Canada) on a feeder layer comprising a 1:1 mixture of irradiated M2-10B4 and S1/S1 mouse fibroblasts. This assay was performed following the protocol provided with the products. 20 LTC-IC frequency was calculated using L-Calc software (Stem Cell Technologies).
Advanced xenograft transplantation NOD/SCID mice were purchased from Shanghai SLAC Laboratory Animal Co. Ltd (SLAC, Shanghai, China). These mice were maintained and handled under sterile conditions at the animal facility in accordance with local regulations. Immunophenotypic analysis of BM cells of mouse recipients BM cells of recipients were flushed down with Iscove's modified Dulbecco's medium (Gibco, Carlsbad, CA, USA) supplemented with 1% bovine serum albumin (Sigma, St Louis, MO, USA). Cells were stained CD45-APC or CD45-PE-Cy7 for engraftment; CD34-PE-Cy7 for total stem/progenitor cells; and CD34-PE-Cy7 and CD38-PE for engrafted HSCs. Stained cells were analyzed or sorted using flow cytometer (Aria II; BD, Franklin Lakes, NJ, USA). All antibodies were obtained from BD Bioscience (San Jose, CA, USA). The detail is described in Supplementary Methods.
Flow sorting of LSCs
LSCs were sorted as previously described. 22 
RESULTS
FEV is expressed only in fetal hematopoietic cells Expression of FEV in hematopoietic cells was initially detected at different developmental stages of zebrafish. 16 Results of wholemount in situ hybridization showed that fev expression was detected in the lateral late mesoderm at 10-somite stage. Figure S3b) .
These results show that FEV is conservatively expressed in embryonic and fetal hematopoietic cells and becomes silent after birth in different species from zebrafish to humans, suggesting that FEV may be a specific regulator of fetal hematopoiesis. Figure 2a) . 16 Transduction efficiencies of the Ctr.V, NSC and iFEV were detected 3 days after viral infection (Figure 2b , top panels), and the transduced cells (GFP + ) were flow-sorted with high purities (Figure 2b , bottom panels). FEV knockdown was determined by RT-PCR (Figure 2c ). The quantitative limiting dilution assay was used to analyze the frequency of LTC-ICs, the most primitive human hematopoietic cells assessable in vitro. FEV knockdown markedly reduced LTC-IC readout compared with that in Ctr.V and NSC settings (Figure 2d ). There is no significant difference between Ctr.V and NSC (Figure 2d ). In line with this result, loss of FEV significantly reduced replatable CFCs as assessed by plating (Figure 2e ) and replating (Figure 2f ) CFC assays.
RNA (iFEV;
The cultured cells (Figure 2b ) were analyzed to determine whether reduction of CFCs and LTC-ICs in iFEV cells could also reflect differences in cell cycle kinetics or cell survival. Results of apoptosis assay (Supplementary Figures S4a and b) and cell cycle analysis ( Supplementary Figures S4c and d) showed no difference between iFEV and Ctr.V cells. These results suggest that FEV is an obligatory regulator of HSC self-renewal.
To further determine the role of FEV in regulating self-renewal in HSCs, total unsorted GFP + and GFP − cells after transduction were transplanted into immunodeficient NOD/SCID mice treated with CD122 antibody (NS122 mice). − (Figures 3e and f) were analyzed. The populations of progenitor and stem cells were lower in iFEV than that in the control. This result indicates that the lower engraftment contribution of iFEV cells may be attributed to impaired self-renewal by FEV knockdown. To consolidate this result, the engrafted GFP + cells from the primary iFEV and Ctr.V recipient mice were flow-sorted and transplanted into secondary recipients. After 10-12 weeks post transplantation, human cell engraftments were analyzed. The details are shown in Table 1 . The iFEV cells failed to reconstitute in secondary recipients, whereas the Ctr.V cells engrafted well, with comparable numbers of cells transplanted (Figures 3g and h) .
To molecularly confirm the regulatory role of FEV in the selfrenewal of fetal HSCs, we comparatively analyzed the differential expression of those genes reported to be essential for the maintenance of fetal HSCs 25, 26 by using RT-qPCR in iFEV and Ctr.V cells (Figure 2b) . With FEV knockdown, the expression of genes SCL, MLL, IKZF1, BMI1 and MEIS1 were significantly reduced (Supplementary Figure S5) , further supporting that FEV is a crucial regulator of HSCs.
FEV expression in leukemic cells is indicative of a prenatal origin
We next investigated the FEV expression in leukemic cells by using the same RT-qPCR. First, we measured FEV expression in infant leukemias (0 − 12 months old) that are almost all prenatal in origin. 13, 27 A total of 53 infant samples were obtained and qualified for the detection of RT-qPCR and data analysis (Table 2  and Supplementary Table S1 ). The results showed that most infant samples (51 in 53) were FEV positive (FEV + ) at a comparable level as in CB CD34 + cells ( Figure 4 and Table 2 ). We then screened for FEV expression in adult leukemias (440 years old) that are presumed to rise postnatally. A total of 11 adult samples were tested for FEV expression by RT-qPCR and data analysis (Table 2  and Supplementary Table S2 ). The results showed that most adult samples (10 in 11) were FEV negative (FEV − ) similarly as detected in normal BM cells ( Figure 4 and Table 2 ). Together, the dramatic difference between infant and adult samples suggests that FEV expression in leukemic cells is indicative of a prenatal origin.
To extend the detection in wider spectrum of pediatric leukemias, we measure the FEV expression in 193 samples of children (1-13 years old), 15 teenagers (13-20 years old) and 3 young adults (20-40 years old) with AML or ALL (Supplementary Table S3 ). The results are summarized in Figure 4 . The expression pattern in children is similar to that in infants, with most samples being FEV + (Table 2) . Surprisingly, all the tested samples of teenagers and young adults were FEV + . The results of FEV positivity suggested that the majority of pediatric leukemias are possibly prenatal in origin. + CD38 − cells in the BM of primary Ctr.V and iFEV mice, representative plots (e) and statistical summary (f); n = 9 (Ctr.V) and n = 7 (iFEV) mice. (g and h) Engraftment contribution of Ctr.V or iFEV cells in secondary recipients by representative flow cytometric plots (g) and statistical summary (h). Note that iFEV cells failed to reconstitute in secondary recipients; n = 5 (Ctr.V) and n = 3 (iFEV) mice. # P40.05, *P o0.05, **P o0.005, ***P o0.001 (Student's t-test). All Data are presented as mean ± s.d.
Considering there was a range of expression levels in the FEV + samples, we took the pediatric samples collected in one hospital (Shanghai Children's Medical Center) for further analysis to determine whether there was any correlation of FEV expression levels with diagnostic factors. A significant correlation between FEV expression levels and leukemia subtype (lymphoid or myeloid) was identified (r = À 0.223, P o 0.001); FEV expression in ALL samples was significantly higher than that in AML samples (Supplementary Figure S6a) . There was no significant correlation of FEV expression levels with age (Supplementary Figure S6b , r = À 0.114, P = 0.071), karyotype (r = 0.074, P = 0.318) and gender (r = À 0.033, P = 0.600). transplantation, the leukemic reconstitution in the mouse BM was analyzed by detecting human CD45. 22, 24 Ctr.V-transduced cells propagated well, whereas iFEV-LMPP and iFEV-GMP cells failed to reconstitute in the BM as shown in the representative flow cytometric plots (Figures 5a and b) and the statistical diagram of the total samples and mice studied (Figures 5c and d) . The results indicate that iFEV impaired the leukemia-propagating capacity of LSCs.
A similar functional assay was also performed on FEV + ALL cells. Previous studies showed that cell fractions containing LSCs with a wide spectrum of immunophenotypes can propagate leukemia. 11, 19, [28] [29] [30] The total leukemic cells of ALL samples in the current study were applied to assess the effect of iFEV on leukemia-propagating ability in NS122 mice. 21 Similar results were obtained; the knockdown of FEV expression in ALL cells markedly impaired the leukemia-propagating capacity in recipient mice (Figures 5e and f) .
The normal human HSCs (Lin − CD34 + CD38 − ) isolated from donor's BM at transplantation were used as a control in the xenotransplantation experiments to determine whether or not iFEV transduction affects hematopoietic reconstitution of normal BM HSCs. The results showed no significant difference in engraftment in mice between Ctr.V and iFEV cells, indicating iFEV treatment did not affect the function of normal HSCs (Supplementary Figures S8a and b) .
Taken together, FEV is expressed in childhood leukemic cells of both AML and ALL, and FEV expression is functionally essential for the leukemia-propagating capacity of LSCs. Treatments such as iFEV transduction may selectively impair LSCs and spare normal BM HSCs.
DISCUSSION
Since the first evidence was reported that leukemogenic mutations occurred in utero, 4 several approaches have been developed to track down the prenatal origin of childhood leukemia; for example, genetic analysis of concordant leukemia of twins 5, 31 and detection of genetic lesions of the neonatal blood in archived Guthrie cards. 5, [32] [33] [34] These studies revealed that 450% of cases of childhood leukemia are prenatal in origin, although these approaches might technically underestimate the frequency. However, because of lack of a feasible diagnostic approach to determine the pre-or postnatal origin of leukemias, the exact frequency and biologic and medical implications of determining prenatal origination remains unknown in pediatric leukemias.
Here, we have addressed these issues by identifying and characterizing FEV.
FEV expression profiles are highly conservative in zebrafish, mice and humans. FEV is active in fetal and neonatal HSCs and silent in postnatal HSCs. We demonstrated that FEV expression is functionally essential to the self-renewal of HSCs. In line with our previous finding, 16 FEV regulates HSC emergence in embryonic development of hematopoietic system and functionally maintains the self-renewal capacity of HSCs in fetal development. We identified FEV as a unique regulator of fetal hematopoiesis. Understanding how the fetal self-renewal machinery in HSCs switches to postnatal one when HSCs migrate to the BM after birth is expected to elucidate the mechanism of how leukemia develops. 35 More interestingly therefore, FEV expression in leukemic cells was positive in most infant patients' samples, whereas rarely positive in adult patients, indicating that FEV-expressed leukemia may be prenatal in origin. By detecting and modifying FEV expression, we investigated the frequency of prenatal origination and explored the potential therapeutic implication in pediatric leukemias. Consistent with the prediction by previous studies, [5] [6] [7] 32, 33 most cases of pediatric leukemias were FEV expression positive, in accord with a prenatal origin. Moreover, FEV was positive in all the tested samples of teenagers and young adults, suggesting that leukemias in these patients who are routinely admitted to adult wards and receive treatment as adult patients may actually be similar to childhood leukemias in terms of etiology and biologic basis and thus therapeutics.
Further analyses of the correlation of FEV expression levels with diagnostic factors in pediatric samples were performed. The results showed that the FEV expression level in ALL was significantly higher than that in AML. Yet, the relevance of the difference remains to be determined, and may be associated with distinct cellular origins or different leukemia-propagating capacity of leukemic cells. Further studies are required to define changes in FEV expression by leukemia subtype of genetic lesions including MLL fusions that may contribute to our understanding of leukemogenesis in terms of the precise period in which the initiating events occur and the covert latency of the disease. 36, 37 More importantly, the results of our xenotransplantation experiments showed that iFEV treatment significantly impaired the leukemia-propagating capacity of LSCs, without affecting hematopoietic reconstitution of normal HSCs. This suggests that FEV may provide a tractable target for therapy in childhood leukemias, killing LSCs and sparing normal HSCs. Therefore, our findings and conceptual views have implications in both etiology and therapeutics of cancer, particularly in childhood and adolescent patients.
